Published in J Virol on March 01, 2004
LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res (2008) 2.38
Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic Acids Res (2007) 1.70
P-TEFb is not an essential elongation factor for the intronless human U2 snRNA and histone H2b genes. EMBO J (2005) 1.66
Regulation of cyclin T1 and HIV-1 Replication by microRNAs in resting CD4+ T lymphocytes. J Virol (2011) 1.32
Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J Virol (2005) 1.30
Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol Cell Biol (2008) 1.26
Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat. PLoS Pathog (2010) 1.16
Cyclin-dependent kinase 9 (Cdk9) of fission yeast is activated by the CDK-activating kinase Csk1, overlaps functionally with the TFIIH-associated kinase Mcs6, and associates with the mRNA cap methyltransferase Pcm1 in vivo. Mol Cell Biol (2006) 1.15
Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J Mol Biol (2008) 1.11
Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene (2007) 1.07
Selective control of gene expression by CDK9 in human cells. J Cell Physiol (2010) 1.06
Molecular strategies to inhibit HIV-1 replication. Retrovirology (2005) 1.05
Induction of the HIV-1 Tat co-factor cyclin T1 during monocyte differentiation is required for the regulated expression of a large portion of cellular mRNAs. Retrovirology (2006) 1.03
P-TEFb- the final frontier. Cell Div (2009) 0.98
HIV-1 replication and latency are regulated by translational control of cyclin T1. J Mol Biol (2011) 0.97
Pivotal role of cardiac lineage protein-1 (CLP-1) in transcriptional elongation factor P-TEFb complex formation in cardiac hypertrophy. Cardiovasc Res (2007) 0.96
Identification of flavopiridol analogues that selectively inhibit positive transcription elongation factor (P-TEFb) and block HIV-1 replication. Chembiochem (2009) 0.95
Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94
Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther (2009) 0.94
Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol (2010) 0.94
High-throughput RNA interference screens integrative analysis: Towards a comprehensive understanding of the virus-host interplay. World J Virol (2013) 0.89
P-TEFb kinase complex phosphorylates histone H1 to regulate expression of cellular and HIV-1 genes. J Biol Chem (2010) 0.87
Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J (2008) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
RNA interference and antiviral therapy. World J Gastroenterol (2007) 0.86
U30 of 7SK RNA forms a specific photo-cross-link with Hexim1 in the context of both a minimal RNA-binding site and a fully reconstituted 7SK/Hexim1/P-TEFb ribonucleoprotein complex. J Mol Biol (2009) 0.86
Herpes simplex virus 1 ICP22 inhibits the transcription of viral gene promoters by binding to and blocking the recruitment of P-TEFb. PLoS One (2012) 0.84
Limited redundancy in genes regulated by Cyclin T2 and Cyclin T1. BMC Res Notes (2011) 0.82
RNA interference approaches for treatment of HIV-1 infection. Genome Med (2015) 0.81
Computational study and peptide inhibitors design for the CDK9 - cyclin T1 complex. J Mol Model (2013) 0.78
The emerging role of long non-coding RNAs in HIV infection. Virus Res (2015) 0.77
Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma. Oncol Lett (2015) 0.75
Positive cyclin T expression as a favorable prognostic factor in treating gastric gastrointestinal stromal tumors. Mol Clin Oncol (2016) 0.75
Development of antibody-modified chitosan nanoparticles for the targeted delivery of siRNA across the blood-brain barrier as a strategy for inhibiting HIV replication in astrocytes. Drug Deliv Transl Res (2017) 0.75
Targeting of CDK9 with indirubin 3'-monoxime safely and durably reduces HIV viremia in chronically infected humanized mice. PLoS One (2017) 0.75
The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther (2017) 0.75
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev (2000) 10.64
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell (1998) 10.14
The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. Nature (1997) 8.86
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Gene silencing in mammals by small interfering RNAs. Nat Rev Genet (2002) 7.80
DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs. Genes Dev (1998) 6.96
Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev (1997) 6.88
5'-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 6.68
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell (1999) 6.34
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
mRNA capping enzyme is recruited to the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev (1997) 5.77
RNAi: nature abhors a double-strand. Curr Opin Genet Dev (2002) 5.74
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol (2000) 5.64
The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature (2001) 5.14
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev (1997) 5.13
7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature (2001) 5.11
Dynamic association of capping enzymes with transcribing RNA polymerase II. Genes Dev (2000) 4.47
The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev (1998) 4.38
Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J (1998) 4.08
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
Mammalian capping enzyme complements mutant Saccharomyces cerevisiae lacking mRNA guanylyltransferase and selectively binds the elongating form of RNA polymerase II. Proc Natl Acad Sci U S A (1997) 3.14
Tackling Tat. J Mol Biol (1999) 3.13
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem (2000) 3.13
Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J (1998) 3.05
A highly purified RNA polymerase II elongation control system. J Biol Chem (2001) 2.84
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med (2002) 2.82
Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem (1999) 2.81
Domains in the SPT5 protein that modulate its transcriptional regulatory properties. Mol Cell Biol (2000) 2.74
HIV-1 auxiliary proteins: making connections in a dying cell. Cell (1998) 2.68
Kin28, the TFIIH-associated carboxy-terminal domain kinase, facilitates the recruitment of mRNA processing machinery to RNA polymerase II. Mol Cell Biol (2000) 2.64
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci U S A (1997) 2.52
The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J Virol (1998) 2.51
Taking a new TAK on tat transactivation. Genes Dev (1997) 2.46
Transcription elongation factor P-TEFb mediates Tat activation of HIV-1 transcription at multiple stages. EMBO J (1998) 2.45
CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes Dev (2002) 2.36
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology (1993) 2.24
Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxyl-terminal domain independently of cyclin-dependent kinase-activating kinase. J Biol Chem (2001) 2.13
Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol (1999) 2.01
Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol (2002) 1.90
DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem (2000) 1.85
Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci U S A (1999) 1.82
RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol (2002) 1.80
Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology (1999) 1.70
Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys (1999) 1.66
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem (2000) 1.59
Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol (2001) 1.48
TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci U S A (2002) 1.44
Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation. J Mol Biol (1999) 1.40
Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci U S A (1999) 1.37
The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev (1998) 1.34
Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes. J Biol Chem (1999) 1.33
Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem (2002) 1.22
Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry (2002) 1.21
Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b. Virology (1999) 1.14
RNA interference of HIV replication. Trends Immunol (2002) 1.08
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54. PLoS Biol (2006) 6.41
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Specific and potent RNAi in the nucleus of human cells. Nat Struct Mol Biol (2005) 3.16
Cellular microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell (2009) 3.05
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Small RNA-mediated regulation of iPS cell generation. EMBO J (2011) 2.95
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature (2003) 2.90
Rhea--a manually curated resource of biochemical reactions. Nucleic Acids Res (2011) 2.87
Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol (2008) 2.83
RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell (2007) 2.72
Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. PLoS Pathog (2008) 2.72
Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog (2006) 2.61
A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. Cell Host Microbe (2009) 2.34
Macrophages archive HIV-1 virions for dissemination in trans. EMBO J (2005) 2.27
The Enzyme Portal: a case study in applying user-centred design methods in bioinformatics. BMC Bioinformatics (2013) 2.14
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature (2006) 2.02
Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion. Nat Cell Biol (2004) 1.91
Small RNAs: regulators and guardians of the genome. J Cell Physiol (2007) 1.86
A dynamin-cortactin-Arp2/3 complex mediates actin reorganization in growth factor-stimulated cells. Mol Biol Cell (2003) 1.80
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol (2005) 1.78
The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci U S A (2013) 1.78
Dynamin 3 is a component of the postsynapse, where it interacts with mGluR5 and Homer. Curr Biol (2003) 1.66
The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg (2008) 1.64
Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog (2007) 1.61
Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol (2004) 1.52
The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc Natl Acad Sci U S A (2002) 1.46
HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China: phylogeographic analyses. PLoS One (2012) 1.44
TAR RNA loop: a scaffold for the assembly of a regulatory switch in HIV replication. Proc Natl Acad Sci U S A (2002) 1.44
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants. J Am Chem Soc (2008) 1.43
Tat stimulates cotranscriptional capping of HIV mRNA. Mol Cell (2002) 1.43
Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem (2004) 1.42
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antivir Ther (2011) 1.41
miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. Int J Oncol (2012) 1.40
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol (2010) 1.39
MicroRNAs encoded by Kaposi's sarcoma-associated herpesvirus regulate viral life cycle. EMBO Rep (2010) 1.34
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe (2008) 1.31
The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog (2012) 1.30
Potent RNAi by short RNA triggers. RNA (2008) 1.29
Deep annotation of mouse iso-miR and iso-moR variation. Nucleic Acids Res (2012) 1.27
Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc Natl Acad Sci U S A (2002) 1.27
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
In-vivo measurement of swine myocardial resistivity. IEEE Trans Biomed Eng (2002) 1.22
Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol (2005) 1.21
Deep molecular characterization of HIV-1 dynamics under suppressive HAART. PLoS Pathog (2011) 1.21
Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry (2002) 1.21
Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology (2003) 1.21
microRNAs modulate iPS cell generation. RNA (2011) 1.19
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol (2006) 1.19
Src kinase regulates the integrity and function of the Golgi apparatus via activation of dynamin 2. Proc Natl Acad Sci U S A (2010) 1.19
In-depth analysis of the interaction of HIV-1 with cellular microRNA biogenesis and effector mechanisms. MBio (2013) 1.18
New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis. Pain (2006) 1.17
Overcoming pharmacologic sanctuaries. Curr Opin HIV AIDS (2013) 1.17
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands. J Med Chem (2006) 1.17
Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem Biol (2007) 1.16
Caveolin-1 interacts directly with dynamin-2. J Mol Biol (2005) 1.14
A kinase inhibitor screen identifies small-molecule enhancers of reprogramming and iPS cell generation. Nat Commun (2012) 1.14
Modest but reproducible inhibition of human immunodeficiency virus type 1 infection in macrophages following LEDGFp75 silencing. J Virol (2006) 1.14
HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol (2003) 1.13
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis. Chem Biol Drug Des (2007) 1.12
Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem (2003) 1.11
Discovery of nonsteroidal anti-inflammatory drug and anticancer drug enhancing reprogramming and induced pluripotent stem cell generation. Stem Cells (2011) 1.08
Dissecting RNA-interference pathway with small molecules. Chem Biol (2005) 1.07
Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. Carcinogenesis (2011) 1.06
Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. J Virol (2005) 1.06
Molecular mechanisms of viral and host cell substrate recognition by hepatitis C virus NS3/4A protease. J Virol (2011) 1.05
Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5. Retrovirology (2004) 1.05
Contact sensing provides a highly accurate means to titrate radiofrequency ablation lesion depth. J Cardiovasc Electrophysiol (2010) 1.04
Caveolae mediate growth factor-induced disassembly of adherens junctions to support tumor cell dissociation. Mol Biol Cell (2009) 1.04
Regulation of anti-phosphatidylserine antibodies. Immunity (2003) 1.03
LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencing. Proc Natl Acad Sci U S A (2010) 1.03
Eps15 mediates vesicle trafficking from the trans-Golgi network via an interaction with the clathrin adaptor AP-1. Mol Biol Cell (2008) 1.02
Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res (2011) 1.02
miR-133b acts as a tumor suppressor and negatively regulates FGFR1 in gastric cancer. Tumour Biol (2013) 1.02